Sources: Alphabet's Verily has been talking with insurers about joint bids for contracts that would involve taking on risk for hundreds of thousands of patients
- The company is looking to take on risk for patient populations and sharing in the upside if it can bring down health-care costs, sources tell CNBC. Tweets: @onceupona Tweets: Adrianna McIntyre / @onceupona : I'm generally skeptical of the “big data is all we need to ~disrupt~ health care” narrative, but color me intrigued by Alphabet entertaining the Medicaid space http://twitter.com/...
Context & Ripple Effects
A year after Temasek's $800M minority-stake investment gave Verily outside capital and an operating-board seat, Alphabet's life-sciences arm is weighing its boldest monetization step yet: joint bids with insurers to take on financial risk for patient populations in the hundreds of thousands, with Medicaid flagged as a target market. Rather than selling tools or studies, Verily would share both the downside and the upside if its data can bend cost curves.
The subsequent record shows how the bet evolved: a push into clinical-trials partnerships with Novartis, Sanofi, Otsuka, and Pfizer, a $700M raise to expand commercial businesses, revenue that reached $470M in nine months of 2022 — followed by wider-than-expected operating losses and planned cost cuts by mid-2023. Risk-bearing was the most capital-intensive path on the table, which is what makes these talks a useful lens on Verily's whole strategy.
First-order effects
- Insurers bidding for large risk contracts gain a partner that can contribute population-data capabilities without building them in-house, while Verily moves from vendor to balance-sheet participant whose revenue now depends on actual cost outcomes.
Second-order effects
- Established population-health analytics vendors face a competitor subsidized by Alphabet's capital — the same dynamic behind Verily's later expansion into trials and connected devices like sensor-embedded shoes — pressuring them to bundle services rather than sell point solutions.
- If Verily wins bids, payers' contract pricing shifts toward splitting realized savings with a data partner, changing how actuarial value is negotiated on government-program populations.
Third-order effects
- The pattern points toward big-tech health units being judged as operating businesses, not moonshots: Verily's 2023 losses and cost-cutting plans show that bearing risk for hundreds of thousands of patients demands sustained capital tolerance that even Alphabet eventually reined in.
- If tech entrants do take on insurance-style risk at scale, regulators overseeing Medicaid managed care gain a new class of counterparty where data practices and financial solvency both become oversight questions.
The trend: Big-tech health divisions are moving from selling data tools to bearing financial risk for care outcomes — a shift whose capital demands are testing whether Alphabet will keep funding the model.